Lee A Y, Wong T M
Arch Int Pharmacodyn Ther. 1987 Apr;286(2):212-5.
The antiarrhythmic potency of naloxone was determined by a screening test using the isolated ischaemic perfused rat heart preparation. The cardiac antiarrhythmic potency CAP50 with 95% confidence limit was 818 nmole/heart (646-985) and relative potency 0.22 compared with 0.35, 0.51 and 1.0 for lidocaine, quinidine and propranolol, respectively. These values are of clinical importance when considering the use of naloxone as an antiarrhythmic agent.
通过使用离体缺血灌注大鼠心脏标本的筛选试验来测定纳洛酮的抗心律失常效力。心脏抗心律失常效力CAP50及其95%置信区间为818纳摩尔/心脏(646 - 985),与利多卡因、奎尼丁和普萘洛尔的相对效力分别为0.35、0.51和1.0相比,纳洛酮的相对效力为0.22。在考虑将纳洛酮用作抗心律失常药物时,这些数值具有临床重要性。